Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.55 |
| ▸ | CD74 | P04233 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522607 | 0.88 | MIF (0.66) | MIFCD74KMT2AMEN1IDO1 | |
| SCHEMBL9047870 | 0.87 | IDO1 (0.68) | MIFKMT2ALMNATSHRMEN1 | |
| SCHEMBL3932904 | 0.85 | IDO1 (0.57) | MIFCD74KMT2AMEN1IDO1 | |
| SCHEMBL11996086 | 0.85 | ALDH1A1 (0.69) | MIFCD74KMT2ATSHRMEN1 | |
| SCHEMBL5308662 | 0.85 | NPC1 (0.55) | MIFKMT2ALMNAMEN1IDO1 | |
| SCHEMBL9371190 | 0.83 | MIF (0.71) | MIFCD74KMT2AIDO1POLB | |
| SCHEMBL5123471 | 0.83 | MIF (0.67) | MIFCD74KMT2AIDO1ALDH1A1 | |
| SCHEMBL1716066 | 0.82 | MIF (0.51) | MIFCD74KMT2AMEN1IDO1 | |
| SCHEMBL3929699 | 0.82 | IDO1 (0.60) | MIFCD74KMT2AIDO1ALDH1A1 | |
| SCHEMBL2860677 | 0.82 | P2RX4 (0.68) | MIFKMT2AMEN1IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-01-07 | — | — | US | disclosed |
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2592933-B1 | MIF INHIBITORS AND THEIR USES | GAWECO ANDERSON (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2592933-B1 | MIF INHIBITORS AND THEIR USES | GAWECO ANDERSON (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9050334-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050334-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050334-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-7173036-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173036-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173036-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-02-06 | — | — | US | disclosed |
| US-3969506-A | BRONCHODILATOR | SANDOZ, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3963720-A | BRONCHODILATORS, TRANQUILLIZERS, SEDATIVEHYPNOTIC AGENTS | SANDOZ, INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3959279-A | ANTIHISTAMINES | SANDOZ, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3936453-A | 1-Substituted-2-disubstituted aminoquin azolin-4(1h)-ones | SANDOZ, INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | MIF, ITGB7, ITGB4 | MIF 1/4885CD74 95/4885KMT2A 4578/4885 |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | MIF 1/4885CD74 52/4885KMT2A 3849/4885 |
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | MIF, ITGB7, ITGB4 | MIF 1/4885CD74 95/4885KMT2A 4578/4885 |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | MIF, ITGB7, ITGB4 | MIF 1/4885CD74 48/4885KMT2A 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.